Chronic Wounds & Ulcers and Platelet-rich plasma (PRP): what the trial registry contains
The ClinicalTrials.gov registry holds 26 records for PRP in Chronic Wounds & Ulcers: 2 recruiting now, 3 labelled Phase 3 or 4, across 10 countries. Snapshot 2026-08-29.
Why this is studied in Chronic Wounds & Ulcers
The registry entries here centre on diabetic foot ulcers, where impaired healing reflects neuropathy, ischaemia and infection together. Cell and vesicle products aim to restore a functional healing environment. This is one of the few areas with a genuine regulatory precedent for advanced wound products, so evidence standards are comparatively well defined.
What PRP means in this table
Platelet-rich plasma is a blood product, not a stem-cell product, though it is routinely sold as part of the same package. Preparation varies enormously between systems — platelet concentration, leukocyte content and activation all differ — so the label describes a category of procedure rather than a defined substance, which is the main reason its trial literature is so inconsistent.
The numbers
Every figure below comes from one reproducible query (diabetic foot ulcer x platelet-rich plasma) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 26 |
| Interventional studies in the sample | 24 |
| Recruiting right now | 2 |
| Completed | 10 |
| Terminated, withdrawn or suspended | 5 |
| Phase 3 or Phase 4 records | 3 |
| Countries with at least one site | 10 |
| Median planned enrolment | 40 participants |
| Largest single planned enrolment | 1,500 participants |
| First / most recent start year | 2008 — 2025 |
How mature is this evidence?
The ladder is partly climbed: 3 confirmatory-phase records against 26 in total, with the remainder concentrated in dose-finding and safety territory.
Registrations do not all survive contact with recruitment — 10 completed here, 5 stopped early, giving a 19% attrition rate.
| Phase label | Records | Share |
|---|---|---|
| Not applicable | 15 | 50% |
| Phase 2 | 6 | 20% |
| Phase 1 | 5 | 17% |
| Phase 3 | 2 | 7% |
| Phase 4 | 1 | 3% |
| Early Phase 1 | 1 | 3% |
Median planned enrolment is 40 participants (largest single study: 1,500). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Across 10 countries with registered sites, United States dominates at roughly 33% — a concentration driven by funding and regulation rather than by clinical outcome.
| Country | Studies with a site there |
|---|---|
| United States | 8 |
| Iran | 3 |
| Egypt | 3 |
| Pakistan | 3 |
| China | 2 |
| United Kingdom | 1 |
| Mexico | 1 |
| Taiwan | 1 |
| Italy | 1 |
| Jordan | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
The sponsor mix is academic (7 academic or hospital, 3 commercial among the most frequent lead sponsors).
- Cytomedix — 3 records
- Mashhad University of Medical Sciences — 2 records
- Peking University Third Hospital — 2 records
- Zagazig University — 1 record
- Multan Medical And Dental College — 1 record
- Mansoura University — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT06810726 — Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ul | Phase 2 | Recruiting | 30 | Estar Medical dba Medical Technologies, LTD | 2025-04-15 |
| NCT05610865 — Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers | Phase 1 | Recruiting | 28 | University of the Punjab | 2020-11-20 |
| NCT02248077 — A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, | Phase 4 | Withdrawn | n/a | Cytomedix | 2014-10 |
| NCT04689425 — Umbilical Cord Blood Mononuclear Cell Gel in the Treatment of Refractory Diabetic Foot Ulcer | Phase 3 | Unknown | 40 | Peking University Third Hospital | 2021-03-30 |
| NCT04315909 — The Effect of Platelet-Rich Plasma-Fibrin Glue in Combination With Vitamin E and C for Treatment of Non-healing Diabetic Foot Ulcers | Phase 2, Phase 3 | Unknown | 24 | Mashhad University of Medical Sciences | 2019-08-28 |
| NCT06680856 — Allogeneic Platelet Rich Plasma (PRP) to Treat Diabetic Foot Ulcers | Phase 1, Phase 2 | Completed | 72 | Ospedale Policlinico San Martino | 2021-02-23 |
| NCT04750837 — Platelet Rich Plasma and Diabetic Foot Ulcer | Phase 2 | Completed | 72 | Zagazig University | 2020-01-16 |
| NCT02972528 — The Use of Allogenic Platelet Rich Plasma for the Treatment of Diabetic Foot Ulcer | Phase 1, Phase 2 | Unknown | 30 | Hanan Jafar | 2018-02-03 |
| NCT02134132 — Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers | Phase 1, Phase 2 | Completed | 30 | Royan Institute | 2012-01 |
| NCT02993809 — Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia | Phase 1 | Unknown | 40 | South China Research Center for Stem Cell and Regenerative M | 2018-03 |
What this page does and does not tell you
None of these numbers say the therapy works. They say how much organised research exists and how far along it is; effect sizes live in published results, not registry entries.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many PRP studies for Chronic Wounds & Ulcers are recruiting right now?
2 of 26 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is PRP an approved treatment for Chronic Wounds & Ulcers?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 26 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on PRP for Chronic Wounds & Ulcers?
3 of 26 records carry a Phase 3 or Phase 4 label and 10 are marked completed. Registrations run from 2008 to 2025.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Chronic Wounds & Ulcers: cell-therapy evidence and registered trials
- How much does stem cell therapy for Chronic Wounds & Ulcers cost? (2026)
- Chronic Wounds & Ulcers stem cell therapy — your questions answered (2026)
- Chronic Wounds & Ulcers: cell-therapy evidence by therapy class
- MSC vs PRP for Chronic Wounds & Ulcers: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.